News and Announcements
Mobilicom Limited Reports Improved Income Figures Coupled with Lower Than Expected Outgoings
- Published April 23, 2018 12:00AM UTC
- Publisher Wholesale Investor
- Categories Company Updates
Key Takeaways:
- Positive Q1 result – improved income figures coupled with lower than expected outgoings
- Maintains strong cash balance of $7.5 million
- New Mobile MESH Network Solution for underground operations with Mobilicom’s Communication Units
- SkyHopper secures two design wins in France & US, reaching major company objective with eighth design win four months earlier than anticipated
- Simultaneous integration of both Mobilicom’s MCU-30 and SkyHopper PRO solution into UAV platforms
- Mobilicom releases MCU-RVT and SkyHopper VU Mobile HD Video & Data Receiver, marking another major company objective for SkyHopper
Mobilicom Limited, the developer of 4G Mobile MESH private networking technology, provides the following summary of its activities in Q1 2018.
Click here to view the full Quarterly Report and the Appendix 4C
About Mobilicom Limited:
Mobilicom designs, develops and markets solutions for mission critical and remote mobile private communication networks without the need for, or use of, any existing infrastructure. Mobilicom’s products and technology merge 4G communication with Mobile MESH technologies into a unified solution, with several product families that have been commercially deployed. Mobilicom’s SkyHopper entity targets the Professional, Commercial and Industrial UAV market.
Company Updates
500 Million Episodes, Limited Treatment: How Patrys is Bridging the Gap in an Underserved Market
In the clinical vocabulary of the Intensive Care Unit, there is perhaps no word that carries as much quiet dread as delirium. It is a “chemical storm” of the brain—an acute dysfunction where the delicate balance between calming and activating signals is scrambled. For the patient, it can be a waking nightmare of hallucinations and […]
The Light Fantastic: Why Invion’s Photodynamic Therapy May Be Attracting Big Pharma’s Attention
Invion Limited is challenging the status quo in oncology with its Photosoft™ platform, a precision therapy that uses light-activated molecules to selectively target cancer cells. By transforming the body’s own immune response and addressing the high costs of current cancer treatments, Invion is positioning itself as a transformative player in the biotech sector. With clinical trials underway and strong institutional partnerships, the company is bridging the gap between scientific breakthrough and accessible, scalable patient care.
From Outback to Boardroom: How SWAN Systems is Codifying Water Stewardship
From the arid deserts of Australia to the boardrooms of global tech giants, SWAN Systems is redefining water efficiency. By bridging the gap between field-level agronomics and autonomous irrigation control, the company is proving that “water-positive” targets can be met with science, data, and a 10x ROI commitment.
Backed By Leading Investment Groups and Family Offices
